摘要
【目的】 探讨舒肝解郁胶囊联合小剂量氯米帕明片治疗抑郁症的临床疗效。【方法】 选取2016年10月到2017年本院收治的96例抑郁症患者为研究对象,根据随机数表法将其分为对照组和观察组,每组各48例。对照组服用氯米帕明片进行治疗,观察组给予舒肝解郁胶囊联合氯米帕明片的治疗方法,疗程均为8周。观察治疗前后两组患者的汉密尔顿抑郁自评量表(HAMD)评分、日常生活能力量表(ADL)评分及不良反应发生情况。【结果】 治疗前对照组、观察组HAMD评分分别为(27.41±2.73)分、(28.19±2.58)分,治疗后观察组HAMD评分为(9.82±2.16)分低于对照组的(18.35±2.49)分,且两组均低于治疗前,差异具有统计学意义(t=3.266,P=0.002<0.05)。观察组总不良反应发生率为10.42%(5/48),低于对照组的29.17%(14/48),两组比较差异具有统计学的意义(χ^2=5.315,P=0.021<0.05)。治疗前对照组、观察组ADL评分分别为(41.23±22.25)分、(42.68±23.09)分,治疗后观察组HAMD评分为(62.83±19.14)分,高于对照组的(53.47±21.97)分,且两组均高于治疗前,差异具有统计学意义(t=-2.226,P=0.028<0.05)。【结论】 舒肝解郁胶囊联合氯米帕明片治疗抑郁症有较好的临床疗效,可改善患者的临床抑郁症状,减轻治疗中的不良反应,提高患者的日常生活能力。
【Objective】 To investigate the curative effect of Shugan Jieyu capsule combined with clomipramine in the treatment of depression. 【Methods】 A total of 96 patients with depression who were admitted to our hospital from October 2016 to October 2017 were divided into the control group and the experimental group according to random number table method. There were 48 patients in the control group and 48 patients in the experimental group. Patients in the control group were treated with clomipramine tablets at conventional dose, while patients in the experimental group were treated with Shugan Jieyu capsules combined with low-dose of clomipramine tablets. Both groups of patients were treated for 8 weeks. The Hamilton Depression Self-rating Scale (HAMD), and Ability of Daily Living Scale (ADL) were observed before and after treatment. 【Results】 The HAMD scores of the control group and the experimental group before treatment were (27.41±2.73) points and (28.19±2.58) points, respectively. After treatment, the HAMD score of the control group was 18.35±2.49 and the score of the experimental group was 9.82±2.16 , which showed lower than before treatment. The differences were statistically significant (t=3.266, P=0.002<0.05). The incidence of total adverse reactions in the control group was 29.17% (5/48) while the incidence of total adverse reactions in the experimental group was 10.42% (14/49). The difference between the two groups was statistically significant (χ^2=5.315, P=0.021<0.05). The ADL scores of the control group and the experimental group were 41.23±22.25 and 42.68±23.09, respectively. After treatment, the HAMD scores of the experimental group and the control group were 62.83±19.14 and 53.47±21.97, respectively,. which were higher than before treatment. The difference was statistically significant (t=-2.226, P=0.028<0.05). 【Conclusion】 Shuganjieyu Capsules combined with clomipramine have a good effect in the treatment of depression, which significantly improves the clinical symptoms of depression in patients, reduces the adverse reactions during treatment, and promotes the daily living ability of patients.
作者
白存海
于丽燕
BAI Cun-hai;YU Li-yan(Department of Psychiatric Shiling Hospital of Zhangjiakou, Hebei 075131 China)
出处
《医学临床研究》
CAS
2019年第1期101-102,105,共3页
Journal of Clinical Research
关键词
抑郁症/药物疗法
抗抑郁药
三环
Depressive Disorder/DT
Antidepressive Agents,Tricyclic
